Enfuvirtid
Klinički podaci | |||
---|---|---|---|
Robne marke | Fuzeon | ||
AHFS/Drugs.com | Monografija | ||
Identifikatori | |||
CAS broj | 159519-65-0 | ||
ATC kod | J05AX07 | ||
PubChem[1][2] | 16130199 | ||
DrugBank | DB00109 | ||
ChemSpider[3] | 16743716 | ||
UNII | 19OWO1T3ZE ![]() | ||
KEGG[4] | D02499 ![]() | ||
ChEBI | CHEBI:608828 ![]() | ||
ChEMBL[5] | CHEMBL525076 ![]() | ||
Hemijski podaci | |||
Formula | C202H298N50O64 | ||
Mol. masa | 4492,1 g/mol | ||
SMILES | eMolekuli & PubHem | ||
| |||
Farmakokinetički podaci | |||
Bioraspoloživost | 84,3% (SC) | ||
Vezivanje za proteine plazme | 92% | ||
Metabolizam | Hepatički | ||
Poluvreme eliminacije | 3.8 sata | ||
Izlučivanje | nepoznato | ||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status | S4 (Au), POM (UK), ℞-only (SAD) | ||
Način primene | Subkutano (SC) |
Enfuvirtid je 36 aminokiselina dug sintetički peptid koji inhibira HIV-1 fuziju sa CD4 ćelijama. On je acetilisan na N-kraju.[6][7][8]
Strukturna formula
Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Reference
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
- ↑ Greenberg ML, Cammack N: Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother. 2004 Aug;54(2):333-40. Epub 2004 Jul 1. PMID 15231762
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. PMID 21059682.
- ↑ Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. PMID 18048412.
Spoljašnje veze
![]() | Portal Medicina |
![]() | Portal Hemija |
![](http://upload.wikimedia.org/wikipedia/commons/thumb/4/4a/Commons-logo.svg/15px-Commons-logo.svg.png)
Enfuvirtid na Wikimedijinoj ostavi
- Enfuvirtide